The IBD SmartSelect Composite Rating for Avadel Pharmaceuticals rose from 94 to 96 Thursday.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. The best stocks tend to have a 95 or better grade as they kick off a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Avadel Pharmaceuticals is not currently near a proper buy zone. See if the stock goes on to form a new chart pattern and offer a new buying opportunity.
One weak spot is the company's 71 EPS Rating, which tracks quarterly and annual earnings-per-share growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company reported 0% earnings-per-share growth for Q2. Top line growth fell to 64%, down from 93% in the prior quarter. The company's next quarterly report is expected on or around Nov. 5.
Avadel Pharmaceuticals earns the No. 13 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Halozyme Therapeutics and Incyte are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
